Get started
Live feed
·
PRReleasevia Quantisnow
Summit Therapeutics Inc. logo

Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

ByQuantisnow·Wall Street's wire, on your screen.
Stocks in this Quantisnow insight

Historical context for SMMT

Across the 26 sessions after earlier SMMT headlines, the stock closed higher 13 times and lower 13 times, with a median move of 4.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.

SMMT close-to-close change in the session after earlier headlines
SessionEarlier headlineSMMTSPY
Oct 21, 2026Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancerand 1 other headline that session-1.6%+0.5%
Oct 19, 2026Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma+6.4%+0.4%
Sep 22, 2026HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026+1.3%-0.0%
Sep 15, 2026Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients-5.5%-0.5%
Sep 14, 2026Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China+5.0%-0.4%
Sep 9, 2026Summit Therapeutics upgraded by Jefferies with a new price target+1.5%-0.5%
Quantisnow market dataNASDAQ
Summit Therapeutics Inc. logo
SMMT
Summit Therapeutics Inc.
Market cap
30-day
Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Listed since
2015
Get push alerts for SMMT

Follow SMMT and get a push notification the moment its next story breaks.

Full SMMT profile on Quantisnow

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SMMT (Summit Therapeutics Inc.) and more on Quantisnow.